Palvella Therapeutics (PVLA) EBIT Margin (2014 - 2024)
Palvella Therapeutics (PVLA) posted quarterly EBIT Margin of 3318.87% for Q1 2024, down 254718.0% year-over-year from N/an in Q2 2023, and down 594.22% quarter-over-quarter from 478.07% in Q4 2023.
Powered by 
Analysis
Palvella Therapeutics (PVLA) EBIT Margin (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has reported EBIT Margin for 11 consecutive years, with 3318.87% the latest figure, recorded in Q1 2024.
- In Q1 2024, EBIT Margin fell 254718.0% year-over-year to 3318.87%; the TTM figure through Sep 2024 stood at 133.13% (down 4499.0% YoY), while the FY2023 annual figure was 30.66%, up 1000952.0% from the prior year.
- EBIT Margin eased to 3318.87% in Q1 2024 per PVLA's latest filing, from 478.07% in the prior quarter.
- Across five years, EBIT Margin topped out at 351.09% in Q4 2020 and bottomed at 8408.03% in Q4 2022.
- Historically, EBIT Margin has averaged 1546.13% across 5 years, with a median of 468.62% in 2021.
- Annual changes were most pronounced in 2022 — EBIT Margin plunged 827776 bps — and 2023, when it surged 792996 bps.
- Palvella Therapeutics' EBIT Margin stood at 351.09% in 2020, then sank by 137 bps to 130.27% in 2021, then sank by 6354 bps to 8408.03% in 2022, then surged by 94 bps to 478.07% in 2023, then slumped by 594 bps to 3318.87% in 2024.
- Business Quant data shows PVLA's EBIT Margin at 3318.87% in Q1 2024, 478.07% in Q4 2023, and 60.49% in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -3,318.87% |
| Dec 31, 2023 | 1,030.48% |
| Sep 30, 2023 | -60.49% |
| Jun 30, 2023 | 10.27% |
| Mar 31, 2023 | -771.69% |
| Dec 31, 2022 | -197.04% |
| Sep 30, 2022 | -226.59% |
| Jun 30, 2022 | -333.42% |
| Mar 31, 2022 | -66.70% |
| Dec 31, 2021 | -130.27% |
| Sep 30, 2021 | -468.62% |
| Jun 30, 2021 | -510.23% |
| Mar 31, 2021 | -38.92% |
| Dec 31, 2020 | -661.21% |
| Sep 30, 2020 | -442.29% |
| Jun 30, 2020 | -41.39% |
| Mar 31, 2020 | -29.08% |
| Dec 31, 2019 | -7.70% |
| Sep 30, 2019 | -19.26% |
| Jun 30, 2019 | -229.37% |